Skip to content

Minimally Invasive Treatments of the Thyroid

Multicenter International Prospective Analysis on Minimally Invasive Treatments of the Thyroid (MIPA- MITT) of of Micropapillary Thyroid Carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06333587
Acronym
MIPA-MITT
Enrollment
270
Registered
2024-03-27
Start date
2022-10-10
Completion date
2035-12-31
Last updated
2024-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary Thyroid Microcarcinoma

Brief summary

This is a prospective cohort study to test Minimally Invasive Treatments of the Thyroid (MITT) as potential alternative to surgery in patients with Papillary Thyroid MicroCarcinoma (PTMC)

Detailed description

Image-guided thermal ablations have been successfully applied in the treatment of several type of tumors, and have been recently proposed as a potential alternative to surgery also in patients with thyroid diseases, and named Minimally Invasive Treatments of the Thyroid (MITT). These minimally invasive treatments, compared to surgical treatment have similar efficacy, fewer complications, better quality of life, and better cosmetic outcomes. These procedures allow precise delivery of the heat locally to the lesion, sparing the surrounding thyroid tissue, and thus minimizing the invasiveness of the treatment and the impact on thyroid function. This study aim to establish a prospective registry of the cases of patients treated with MITT for a Papillary Thyroid MicroCarcinoma (PTMC), in order to validate the safety of the procedure and to set the basis for collecting long term results in a large cohort of patients.

Interventions

image-guided thermal ablation in patients with diagnosis of micropapillary thyroid carcinoma

Sponsors

European Institute of Oncology
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \> 18years * Patients with diagnosis of papillary thyroid microcarcinoma, citologically proven, suitable for MITT. * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion. * Patients must be accessible for follow-up

Exclusion criteria

* Tumors \> 1 cm, other citological type, refusal of MITT, unsuitable for MITT, unmanageable coagulative disorders * Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study

Design outcomes

Primary

MeasureTime frameDescription
The proportion of patients with major complications occurring within one month after the date of intervention1 monthComplications will be reported according to modified Society of Interventional Radiology (SIR) classification

Secondary

MeasureTime frameDescription
Percentage of patients with local recurrence at 10 years10 yearsEvaluation of disease free survival (DFS): percentage of patient whith a local recurrence at 10 years of follow up
Percentage of patients with distant metastasis at 10 years10 yearsEvaluation of disease free survival (DFS): percentage of patient whith distant metastasis at 10 years of follow up
Percentage of patients died at 10 years10 yearsEvaluation of Overall Survival (OS): Percentage of patients died at 10 years

Countries

Italy

Contacts

Primary ContactGiovanni Mauri
giovanni.mauri@ieo.it+390294372691

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026